Trial reportJournal of affective disorders2013
Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder.
Trial report in Journal of affective disorders, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies.The lancet. Psychiatry · 2023Pooled it
- Pooled it
- Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
- The impact of intraoperative esketamine infusion on postoperative sleep in patients undergoing general surgery.BMC anesthesiology · 2025Trial
- Ketamine induces multiple individually distinct whole-brain functional connectivity signatures.eLife · 2024Trial
- Clinical predictors of ketamine response in treatment-resistant major depression.The Journal of clinical psychiatry · 2014Trial
- Phenotypic Variability in Slow-Wave Sleep in Depression: Associations With Clinical Profiles and Disorder Severity.Journal of sleep research · 2026Article
- The mPFC molecular clock mediates the effects of sleep deprivation on depression-like behavior and regulates sleep consolidation and homeostasis.Molecular psychiatry · 2026Article
- Serum BDNF, depressive symptoms, sleep quality, and cognitive function: a study on their impact and predictive value for suicidal ideation in bipolar depressive disorder patients.European archives of psychiatry and clinical neuroscience · 2026Article
- The relationship between resting EEG features and physical exercise among university students with depressive symptoms.Scientific reports · 2025Article
- Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action.Current psychiatry reports · 2024Review
- Sleep Delta power, age, and sex effects in treatment-resistant depression.Journal of psychiatric research · 2024Article
- Article
- Construction of a resting EEG-based depression recognition model for college students and possible mechanisms of action of different types of exercise.BMC psychiatry · 2023Article
- (S)-Ketamine but Not (R)-Ketamine Shows Acute Effects on Depression-Like Behavior and Sleep-Wake Architecture in Rats.The international journal of neuropsychopharmacology · 2023Article
- An exploration of actigraphy in the context of ketamine and treatment-resistant depression.International journal of methods in psychiatric research · 2023Article
- Targeting Slow Wave Sleep Deficiency in Late-Life Depression: A Case Series With Propofol.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2023Article
- Protocol for the Ketamine for Postoperative Avoidance of Depressive Symptoms (K-PASS) feasibility study: A randomized clinical trial.F1000Research · 2022Article
- Correlating electroconvulsive therapy response to electroencephalographic markers: Study protocol.Frontiers in psychiatry · 2022Article
- Key considerations in the pharmacological management of treatment-resistant depression.Expert opinion on pharmacotherapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundElectroencephalographic (EEG) sleep slow wave activity (SWA; EEG power between 0.6 and 4Hz) has been proposed as a marker of central synaptic plasticity. Decreased generation of sleep slow waves--a core feature of sleep in depression--indicates underlying plasticity changes in the disease. Various measures of SWA have previously been used to predict antidepressant treatment response. This study examined the relationship between baseline patterns of SWA in the first two NREM episodes and antidepressant response to an acute infusion of the N-methyl-d-aspartate (NMDA) antagonist ketamine.
methodsThirty patients (20M, 10F, 18-65) fulfilling DSM-IV criteria for treatment-resistant major depressive disorder (MDD) who had been drug-free for two weeks received a single open-label infusion of ketamine hydrochloride (.5mg/kg) over 40 min. Depressive symptoms were assessed with the Montgomery-Asberg Depression Rating Scale (MADRS) before and after ketamine infusion. Sleep recordings were obtained the night before the infusion and were visually scored. SWA was computed for individual artifact-free NREM sleep epochs, and averaged for each NREM episode. Delta sleep ratio (DSR) was calculated as SWA(NREM1)/SWA(NREM2).
resultsA significant positive correlation was observed between baseline DSR and reduced MADRS scores from baseline to Day 1 (r=.414, p=.02). LIMITATIONS: The sample size was relatively small (N=30) and all subjects had treatment-resistant MDD, which may limit the generalizability of the findings. Further studies are needed to replicate and extend this observation to other patient groups.
conclusionsDSR may be a useful baseline predictor of ketamine response in individuals with treatment-resistant MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.